###### Article summary

Article focus
=============

-   To analyse the common gene expression profile in primary cell cultures of dermal fibroblasts from patients suffering any of the clinical presentation of the human syndrome of coenzyme Q~10~ (CoQ~10~) deficiency (primary or secondary CoQ~10~ deficiency).

-   To determine why CoQ~10~ treatment, the current therapy for all forms of CoQ~10~ deficiency, restored respiration but not all the clinical phenotypes.

-   To investigate the stable genetic cause responsible for the survival adaptation to mitochondrial dysfunction owing to CoQ~10~ deficiency.

Key messages
============

-   The mitochondrial dysfunction owing to CoQ~10~ deficiency induces a stable survival adaptation of somatic cells in patients at early or postnatal development by epigenetic modifications of chromatin. Deficient cells unable to maintain this survival state during differentiation would die contributing to the pathological phenotype.

-   Supplementation with CoQ~10~ restores respiration through enhanced sugar rather than lipid metabolism; partially restores stress response, immunity, cell death and apoptotic pathways; and does not affect cell cycle, cell growth, and differentiation and development pathways.

-   Survival transcriptome in the CoQ~10~ deficiency syndrome is acquired by epigenetic modifications of DNA: DNA-demethylated genes corresponded to unaffected genes by CoQ~10~ treatment, whereas those with unchanged DNA-methylation pattern corresponded to genes with responsive expression to CoQ~10~ supplementation. These results would approach to explain the incomplete recovery of clinical symptoms after CoQ~10~ treatment, at least in some patients.

Strengths and limitations of this study
=======================================

-   Human CoQ~10~ deficiencies are considered rare diseases with low prevalence, which limits the sample size.

-   The genetic heterogeneity of this disease is owing to mutations in any of the 11 genes directly involved in the synthesis of CoQ~10~ inside mitochondria, or other mutations altering somehow the mitochondria and its metabolism, affecting their inner CoQ~10~ synthesis as a side effect, will course with CoQ~10~ deficiency.

-   Among this genetic heterogeneity, all cells showed a common transcriptomic profile that justified their pathological phenotype, responded equally to CoQ~10~ treatment and presented the same DNA methylation pattern.

Introduction {#s1}
============

Coenzyme Q~10~ (CoQ~10~) is a small electron carrier which is an essential cofactor for several mitochondrial biochemical pathways such as oxidative phosphorylation, β-oxidation and pyrimidine nucleotide biosynthesis. CoQ~10~ biosynthesis depends on a multienzyme complex[@R1] that involves at least 11 proteins encoded by COQ genes. Mutations in any of these genes cause primary CoQ~10~ deficiencies, which are clinically heterogeneous mitochondrial diseases.[@R2] Clinical presentations include encephalomyopathy with lipid storage myopathy and myoglobinuria,[@R3] ataxia and cerebellar atrophy,[@R4] severe infantile encephalomyopathy with renal failure,[@R5] isolated myopathy,[@R6] and nephrotic syndrome.[@R7] Secondary CoQ~10~ deficiency has also been associated with diverse mitochondrial diseases.[@R8; @R9; @R10; @R11; @R12; @R13] In all of these conditions, CoQ~10~ supplementation partially improves symptoms[@R14] [@R15] and usually induces a return to normal growth and respiration in CoQ~10~-deficient fibroblasts.[@R8] [@R16] [@R17] Adaptation of somatic cells to CoQ~10~ deficiency may affect both onset and course of the disease. We document common transcriptomic profile alterations in somatic cells of CoQ-deficient patients, their response to CoQ~10~ supplementation, and the relationship with the DNA methylation status of specific genes.

Materials and methods {#s2}
=====================

Cells {#s2a}
-----

Primary skin fibroblasts from CoQ~10~-deficient patients and from aged-matched controls, at similar culture passage, were cultured at 37°C using Dulbecco\'s Modified Eagle Medium (DMEM) 1 g/l glucose, [l]{.smallcaps}-glutamine and pyruvate (Invitrogen, Prat de Llobregat, Barcelona) supplemented with an antibiotic/antimycotic solution (Sigma Chemical Co, St Louis, Missouri) and 20% fetal bovine serum (FBS, Linus). When required, CoQ~10~ prediluted in FBS was added to the plates at a final concentration of 30 µM (CoQ~10~, Synthetic Minimum 98%, high-performance liquid chromatography, Sigma). We studied five patients with primary CoQ~10~ deficiency: two siblings harboured a homozygous p.Y297C mutation in the *COQ2* gene,[@R5] other with a pathogenic mutation (c.483G\>C) in the *COQ4* gene (this paper), and another one with haploinsufficiency of *COQ4*.[@R18] Patients with secondary CoQ~10~ deficiency included: a mitochondrial encephalopathy, lactic acidosis and stroke-like episodes patient harbouring the m.3243A\>G in the mitochondrial tRNA^Leu(UUR)^ with 43% heteroplasmy level,[@R8] a patient with mtDNA depletion syndrome[@R12] and a third patient with ataxia of unknown origin.[@R4] [Table 1](#BMJOPEN2012002524TB1){ref-type="table"} summarises the clinical phenotype and biochemical studies of these patients.

###### 

Clinical phenotype and biochemical studies performed in patients with coenzyme Q~10~ deficiency

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient/cells\*                       Clinical phenotype                                                                                                                                             Biochemical studies (% with respect to mean reference values)                                                                                                                                                 Effect of CoQ~10~ supplementation†                                                                                                     Reference as cited in the text   Array and epigenetic code
  ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ---------------------------
  Human dermal skin fibroblast          Healthy volunteers                                                                                                                                             *Reference values*                                                                                                                                                                                            *Reference values*                                                                                                                     [@R12]                           \#2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \#HDF\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \#control

  12-year-old girl                      Ataxia and cerebellar atrophySecondary CoQ~10~ deficiency                                                                                                      17% CoQ~10~ in muscle31% mt-RC complex I+III (muscle)46% mt-RC complex II+III (muscle)22% CoQ~10~ in fibroblast24% CoQ~10~ biosynthesis rateROS production (three fold)                                       Improvement of neurological assessmentNo biochemical studies performed                                                                 [@R4]                            \#1

  33-month-old boy(his sister below)    Corticosteroid-resistant nephropathyProgressive encephalomyopathyCOQ2 gene mutation (c.890A\>G)Primary CoQ~10~ deficiency                                      23% CoQ~10~ in muscle19% mt-RC complex I+III (muscle)32% mt-RC complex II+III (muscle)17% CoQ~10~ in fibroblast10% CoQ~10~ biosynthesis rate57% mt-RC complex II+III (cells)                                  Improvement of neurological assessment but not the renal dysfunctionRecovery of cell growthImprovement of 35% complex II+III (cells)   [@R5]\                           \#3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            [@R17]\                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            [@R12] case 3                    

  9-month-old girl(her brother above)   Corticosteroid-resistant nephropathyCOQ2 gene mutation (c.890A\>G)Primary CoQ~10~ deficiency                                                                   29% CoQ~10~ in fibroblast15% CoQ~10~ biosynthesis rate60% mt-RC complex II+III (cells)                                                                                                                        Improvement of 25% complex II+III (cells)Recovery of cell growth                                                                       [@R17]\                          \#5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            [@R12] case 4                    

  Boy                                   MELAS (A3243G mutation)Secondary CoQ~10~ deficiency                                                                                                            58% CoQ~10~ in fibroblast35% mt-RC complex I (cells)41% mt-RC complex II+III (cells)12% mt-RC complex IV (cells)60% mt-ΔΨ70% mitochondrial massROS production (\>2-fold)Defective autophagosome elimination   Recovery of mt-RCRecovery of ATP productionNo ROS production                                                                           [@R8]                            \#4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \#MEL+Q

  10-day-old boy                        mtDNA depletion syndromeNeonatal encephalopathySecondary CoQ~10~ deficiency                                                                                    20% CoQ~10~ in muscle32% mt-RC complex I+III (muscle)19% mt-RC complex II+III (muscle)15% CoQ~10~ in fibroblast85% mt-RC complex II+III (cells)                                                               Improvement of 41% complex II+III (cells)Recovery of cell growth                                                                       [@R34]                           \#ELO\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \#ELO+Q

  3-year-old boy                        Dysmorphic featuresVentricular septal defect and weaknessHypotonia and hyporeactivityModerate mental retardationCOQ4 gene deletionPrimary CoQ~10~ deficiency   40% CoQ~10~ in fibroblast44% CoQ~10~ biosynthesis rate64% mt-RC complex I+III (cells)58% mt-RC complex II+III (cells)                                                                                         Improvement in muscle tone and strengthHe began to speak and walk                                                                      [@R18]                           \#GIO

  Girl                                  COQ4 gene mutation (c.483G\>C)RhabdomyolysisPrimary CoQ~10~ deficiency                                                                                         18% CoQ~10~ in fibroblast                                                                                                                                                                                     Recovery of both complex I+III activity and growth of fibroblasts                                                                      This paper                       \#SIL+Q\#epi

  Girl                                  AtaxiaSecondary CoQ~10~ deficiency                                                                                                                             38% CoQ~10~ in fibroblast                                                                                                                                                                                     Improvement of ATP synthesis                                                                                                           [@R12] case 1                    \#SOF+Q\#epi
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Cultured at 37°C using DMEM 1 g/l glucose, [l]{.smallcaps}-glutamine, pyruvate (Invitrogen) plus antibiotic/antimycotic solution (Sigma) and 20% fetal bovine serum (FBS, Linus).

†CoQ~10~ prediluted in FBS was added to the plates at a final concentration of 30 µM (coenzyme Q~10~, Synthetic Minimum 98%, high-performance liquid chromatography, Sigma).

CoQ~10~, Coenzyme Q~10~; MELAS, mitochondrial encephalopathy, lactic acidosis and stroke-like episodes; mtDNA, mitochondrial DNA; mt-RC, mitochondrial respiratory chain; ROS, reactive oxygen species.

Transcriptome analysis {#s2b}
----------------------

RNA extraction, probe synthesis and hybridisation with two independent expression arrays (GeneChip Human Genome U133 Plus 2.0 and GeneChip Human Gene 1.0 ST, Affymetrix) were used as described.[@R19] Gene expression was validated by the MyiQ Single Color Real Time PCR Detection System (Biorad). See supplementary methods for full description.

Data had been deposited with the NCBI-GEO database, at <http://www.ncbi.nlm.nih.gov/geo/>, accession number GSE33941 (this SuperSeries is composed of two subset Series, see online [supplementary table S7](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1) for an explanation).

Statistical analyses were performed comparing each signal of patient\'s fibroblasts RNA with the corresponding signal of control RNA by two different approaches. The main statistical analysis for both GeneChip Human Genome U133 Plus 2.0 Array and GeneChip Human Gene 1.0 ST Array was achieved as previously described,[@R19] which selects the most significant genes commonly and equally regulated in all samples using very stringent parameters. In a few special cases, other unselected but regulated genes were studied because of their role in specific processes and pathways. They were equally described in [table 2](#BMJOPEN2012002524TB2){ref-type="table"}. The second statistical analysis approach for the Gene Ontology (GO) study was performed as previously described[@R20] and analyses the most altered biological processes and pathways using a lower stringency analysis, which permits to select the hundred most altered GOs in different functional categories (see online [supplementary table S4](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)) and the hundred more distorted pathways (see online [supplementary table S5](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)) that had been regulated in CoQ~10~-deficient cells. GO regulated in both independent analysis of primary and secondary CoQ~10~ deficiencies (see online [supplementary table 3](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)), and those regulated by CoQ~10~ supplementation (see online [supplementary table S9](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)) were studied using the GORILLA software (Gene Ontology enrichment analysis and visualisation tool), at <http://cbl-gorilla.cs.technion.ac.il/.>[@R21] Full description of statistical analysis be found in the [supplementary material](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1).

###### 

Differentially expressed genes in coenzyme Q~10~ deficiency

  Gene symbol\*                     Gene title                                                   FC†      FC‡     CoQ~10~§   Q-RT-PCR¶   CoQ~10~\*\*
  --------------------------------- ------------------------------------------------------------ -------- ------- ---------- ----------- -------------
  Mitochondrial metabolism                                                                                                               
   C7orf55                          Chromosome 7 open reading frame 55                           −2.1     nc      --                     
   BRP44                            Brain protein 44                                             2.0      2.3     U          8.0         --2-fold
   C10orf58                         Chromosome 10 open reading frame 58                          −19.5    −1.6    pR                     
  NADH mobilisation                                                                                                                      
   CYB561                           Cytochrome *b*561                                            −1.3     nc      O                      
   CYB5A                            Cytochrome *b*5-A                                            −1.4     −1.5    U                      
   CYB5R1                           Cytochrome *b*5 reductase 1                                  −1.3     nc      U                      
   CYB5R2                           Cytochrome *b*5 reductase 2                                  −1.4     −1.9    U                      
   CYB5R3                           Cytochrome *b*5 reductase 3                                  −1.4     −1.6    R                      
   CYB5R4                           Cytochrome *b*5 reductase 4                                  −1.3     −1.6    R                      
  Lipid metabolism                                                                                                                       
   FDFT1                            Farnesyl-diphosphate farnesyltransferase 1                   −2.3     −1.5    U          −4.3        +2-fold
   IDI1                             Isopentenyl-diphosphate δ isomerase 1                        −2.1     nc      U                      
   CH25H                            Cholesterol 25-hydroxylase                                   −10.8    −3.2    O          −1.3        --3-fold
   RSAD2                            Radical *S*-adenosyl methionine domain containing 2          −6.8     1.4     pR                     
   INSIG1                           Insulin-induced gene 1                                       −2.6     1.7     O                      
   LDLR                             Low density lipoprotein receptor                             −3.0     −1.8    pR                     
   SQLE                             Squalene epoxidase                                           −2.5     nc      U                      
   SCD                              Stearoyl-coenzyme A desaturase (δ-9-desaturase)              −3.3     nc      U                      
  Insulin metabolism                                                                                                                     
   CPE                              Carboxypeptidase E                                           10.0     2.5     pR                     
   PAPPA                            Pregnancy-associated plasma protein A, pappalysin            2.5      1.7     R          4.8         --5-fold
   PCSK2                            Proprotein convertase subtilisin/kexin type 2                −75.5    −4.3    O                      
  Other metabolism                                                                                                                       
   SCIN                             Scinderin                                                    −5.4     −1.4    O                      
   PYGL                             Phosphorylase, glycogen; liver                               −2.5     −1.6    R                      
   SLC40A1                          Solute carrier family 40 (iron-regulated transporter)        7.6      2.9     R                      
   QPRT                             Quinolinate phosphoribosyltransferase                        −3.4     nc      R                      
   ATP8B1                           ATPase, class I, type 8B and member 1                        2.4      nc      pR                     
  Cell cycle                                                                                                                             
   *POSTN*                          Periostin, osteoblast specific factor                        73.8     153.9   U          238.2       --20%
   VEGFA                            Vascular endothelial growth factor A                         2.9      nc      --                     
   SEMA5A                           Semaphorin 5A, receptor for cell growth                      3.6      1.6     pR                     
   AEBP1                            AE binding protein 1                                         66.1     nc      R                      
   CSRP2                            Cysteine and glycine-rich protein 2                          5.3      1.5     R                      
   DOK5                             Docking protein 5                                            6.5      1.6     U                      
   MID1                             Midline 1 (Opitz/BBB syndrome)                               3.9      4.4     U                      
   CHURC1                           Churchill domain containing 1                                3.5      nc      --                     
   CREG1                            Repressor 1 of E1A-stimulated genes                          3.0      1.3     R                      
   RUNX1                            Runt-related transcription factor 1 (aml1 oncogene)          1.9      1.6     --                     
   BHLHB5                           Basic helix-loop-helix domain containing; class B, 5         −6.1     −1.4    --                     
   IFITM1                           Interferon induced transmembrane protein 1 (9--27)           −3.8     −3.7    O                      
   EDN1                             Endothelin 1                                                 −3.0     nc      U                      
   MATN2                            Matrilin 2                                                   −9.2     nc      U                      
   *MCAM*                           Melanoma cell adhesion molecule                              −6.7     −3.0    R          −10.9       +10%
   MKX                              Mohawk homeobox                                              −4.5     −1.5    --                     
   PSG6                             Pregnancy specific β-1-glycoprotein 6                        2.6      nc      --                     
   DCN                              Decorin                                                      2.0      −1.6    --                     
   PKP4                             Plakophilin 4                                                2.0      1.4     U                      
   *EFEMP1*                         EGF-containing fibulin-like extracellular matrix protein 1   13.2     2.2     pR                     
   *VCAN*                           Versican                                                     2.8      2.7     --         4.6         +10%
   SMARCA1                          Component of SWI/SNF chromatin complex, member A1            −1.3     nc      pR                     
   SMARCA4                          Component of SWI/SNF chromatin complex, member A4            −1.9     nc      pR                     
   CDK6                             Cyclin-dependent kinase 6, overexpressed in tumour           1.4      2.9     U                      
   CDKN1A                           P21, inhibitor of CDK                                        −9.2     −2.1    U                      
   CDKN1C                           P57, inhibitor of CDK                                        −2.6     −1.3    R                      
   CDKN3                            Inhibitor of CDK, overexpressed in cancer cells              1.9      2.7     U                      
   CD31                             Cell surface antigen                                         −1.8     −1.5    R                      
   RB1                              Retinoblastoma protein                                       −1.4     nc      R                      
   E2F7                             E2F transcription factor 7                                   3.6      nc      U                      
   E2F8                             E2F transcription factor 8                                   2.2      nc      U                      
   FST                              Follistatin                                                  2.6      1.4     O                      
  Development and differentiation                                                                                                        
   BDNF                             Brain-derived neurotrophic factor                            −2.9     nc      pR                     
   GRP                              Gastrin-releasing peptide                                    −263.6   nc      --                     
   NTNG1                            Netrin G1                                                    −8.3     1.8     U                      
   PTN                              Pleiotrophin (neurite growth-promoting factor 1)             −2.7     nc      R                      
   FOXQ1                            Forkhead box Q1                                              −6.5     nc      --                     
   HOXA11                           Homeobox A11                                                 −4.3     −2.4    U                      
   HOXC9                            Homeobox C9                                                  −4.8     −2.0    U                      
   LHX9                             LIM homeobox 9                                               −93.0    −1.5    U                      
   SP110                            SP110 nuclear body protein                                   −2.5     nc      pR                     
   P2RY5                            Purinergic receptor P2Y; G-protein coupled, 5                −4.4     −1.3    pR                     
   TSPAN10                          Tetraspanin 10                                               −10.1    nc      --                     
   EPSTI1                           Epithelial stromal interaction 1                             −5.2     −1.4    R                      
   TSHZ1                            Teashirt zinc finger homeobox 1                              −2.8     nc      R                      
   *KRT34*                          Keratin 34                                                   −5.3     −7.6    R          −5.7        --60%
   TPM1                             Tropomyosin 1 (α)                                            −1.8     1.7     --                     
   FOXP1                            Forkhead box P1                                              2.3      nc      --                     
   LMCD1                            LIM and cysteine-rich domains 1                              3.8      nc      U                      
  Cell resistance to stress                                                                                                              
  ** ***CYP1B1*                     Cytochrome P450, family 1B and polypeptide 1                 4.5      1.5     --         7.0         --5-fold
   MGC87042                         Similar to six epithelial antigen of prostate                12.2     --      R                      
   TMEM49                           Transmembrane protein 49/microRNA 21                         1.9      nc      --                     
   RAD23B                           RAD23 homologue B (*Saccharomyces cerevisiae*)               2.2      nc      R                      
   TXNIP                            Thioredoxin-interacting protein                              2.0      −4.9    --                     
   SGK1                             Serum/glucocorticoid regulated kinase 1                      3.4      1.5     --                     
   SOCS3                            Suppressor of cytokine signalling 3                          −3.6     nc      R                      
   RHOU                             Ras homologue gene family. member U                          −8.3     nc      O                      
  Apoptosis                                                                                                                              
   AIM1                             Absent in melanoma 1                                         −4.5     −1.4    O                      
   APCDD1                           Adenomatosis polyposis coli down-regulated 1                 −6.4     −1.8    O                      
   MAGED1                           Melanoma antigen family D, 1                                 −1.7     nc      U                      
   MAGED4/4B                        Melanoma antigen family D, 4/4B                              −5.0     −1.6    U                      
   RAC2                             Small GTP-binding protein Rac2 (rho family)                  −2.3     −1.3    U                      
   TRIM55                           Tripartite motif-containing 55                               −11.7    −1.6    U                      
   IFI6                             Interferon, α-inducible protein 6                            −4.9     −1.3    R                      
   *XAF1*                           XIAP associated factor-1                                     −3.0     −1.5    R                      
   *TNFRSF10D*                      Tumour necrosis factor receptor superfamily 10D              2.4      2.6     U          15.1        +20%
   SFRP1                            Secreted frizzled-related protein 1                          8.7      2.5     U          11.8        --2-fold
  Signalling                                                                                                                             
   ARL4C                            ADP-ribosylation factor-like 4C                              3.8      1.6     pR                     
   USP53                            Ubiquitin specific peptidase 53                              4.2      1.7     --                     
   GABBR2                           γ-aminobutyric acid B receptor, 2                            13.8     2.0     U                      
   CNGA3                            Cyclic nucleotide gated channel α-3                          −67.3    nc      --                     
   GNG2                             G-protein, γ-2                                               −4.2     1.4     pR                     
   HERC6                            Hect domain and RLD 6                                        −7.4     −1.4    R                      
   MLPH                             Melanophilin                                                 −8.5     −1.9    R                      
   NCK2                             NCK adaptor protein 2                                        −1.7     nc      --                     
   PARP14                           Poly (ADP-ribose) polymerase family, member 14               −3.1     −1.5    --                     
  Immunity                                                                                                                               
   CDC42SE2                         CDC42 small effector 2                                       −2.8     nc      --                     
   LY6K                             Lymphocyte antigen 6 complex, locus K                        −4.7     1.4     --                     
   GALNAC4S-6ST                     B cell RAG associated protein                                −17.3    −2.5    O                      
   TNFSF4                           Tumour necrosis factor superfamily, member 4                 −5.9     nc      --                     
   TRIM14                           Tripartite motif-containing 14                               −4.5     nc      --                     
   BTN3(A2/A3)                      Butyrophilin 3 (A2/A3)                                       −2.0     −1.3    R                      
   IFI27                            Interferon, α-inducible protein 27                           −9.8     nc      O                      
   IFI44                            Interferon-induced protein 44                                −3.3     −2.3    R                      
   IFI44L                           Interferon-induced protein 44-like                           −15.0    −1.9    R                      
   IFIT1                            Interferon-induced protein (tetratricopeptide repeats 1)     −5.3     nc      --                     
   IFIT3                            Interferon-induced protein (tetratricopeptide repeats 3)     −3.5     −1.7    R                      
   GBP1                             Guanylate binding protein 1, interferon-inducible            −2.7     --      --                     
   ISG15                            ISG15 ubiquitin-like modifier                                −6.4     nc      R                      
   MX1                              Myxovirus resistance 1                                       −7.4     −1.8    pR                     
   MX2                              Myxovirus resistance 2                                       −6.1     −3.0    pR                     
   OAS1                             2′,5′-oligoadenylate synthetase 1, 40/46 kDa                 −5.1     −4.9    R                      
   OAS2                             2′-5′-oligoadenylate synthetase 2, 69/71 kDa                 −6.2     −1.6    R                      
   OAS3                             2′-5′-oligoadenylate synthetase 3, 100 kDa                   −3.6     −1.3    R                      
   OASL                             2′-5′-oligoadenylate synthetase-like                         −3.1     −2.6    R                      
   PSMB9                            Proteasome subunit, β-type, 9                                −1.8     nc      U                      

\*In italic letter, biomarkers used in several types of cancer as described by Yoo and collaborators.[@R28] See the text for more information.

†Full change (FC) in the comparative analysis ran with Affymetrix GeneChip Human Genome U133 Plus 2.0 Array. Values represent the FC (mean) for each gene corresponding to different patient samples (SAM analysis; R=1.5; false discovery rate (FDR)=0%). In parenthesis, FC of non-significant genes by the statistical threshold used, which were selected owing to their role in specific processes and pathways (see the text for full details). In the case of different probes selected for one gene, values represent the mean of FC for each probe (see online [supplementary table S1](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1) for full details).

‡FC in the comparative analysis ran with Affymetrix Gene Chip Human Gene 1.0 ST Array. In parenthesis, FC of non-significant genes by the statistical threshold used. Genes with no change (nc).

§Effect of coenzyme Q~10~ (CoQ~10~) supplementation on gene expression in CoQ~10~ deficiency: unaffected genes by CoQ~10~ treatment (U); genes that restored the expression either partially (pR) or completely (R); genes with opposite regulation than in CoQ~10~ deficiency (O); and specifically regulated genes only after CoQ~10~ supplementation (S). Genes non-affected by CoQ~10~ supplementation (−). See the text and online [supplementary table S8](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1) for full details.

¶FC in gene expression analysed by quantitative real time PCR (Q-RT-PCR). See [supplementary material and table S11](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1) for primer sequence.

\*\*Effect of CoQ~10~ supplementation on mRNA levels analysed by Q-RT-PCR. Positive values, increase on gene expression; negative values, decrease on gene expression.

AE binding protein 1, adipocyte enhancer binding protein 1; aml1 oncogene, acute myeloid leukaemia 1 oncogene; EGF-containing fibulin-like extracellular matrix protein 1, elongation factor G-containing fibulin-like extracellular matrix protein 1; small GTP-binding protein Rac2 (rho family), small guanosine triphosphate-binding protein Rac2 (rho family); SP110 nuclear body protein, specificity protein-110 nuclear body protein.

Epigenetic analysis {#s2c}
-------------------

DNA (CpG) methylation analysis was performed using a base-specific cleavage reaction with bisulfite combined with mass spectrometric analysis (MassCLEAVE). For the statistical analysis, the CpGs' methylation degree for each gene was analysed with the MultiExperiment Viewer software developed by Saeed.[@R22] See supplementary methods for full description.

Results {#s3}
=======

Transcriptome analysis {#s3a}
----------------------

We studied skin fibroblasts from four patients with primary CoQ~10~ deficiency and three patients with secondary CoQ~10~ deficiency ([table 1](#BMJOPEN2012002524TB1){ref-type="table"}). We analysed the transcriptomic profiles and compared them with those of cells from age-matched control individuals, and evaluated the modifications induced by supplementation with 30 μM CoQ~10~ for 1 week to allow recovery of ATP levels.[@R8] [@R16] [@R17] A very stringent analysis selected the most significant genes displaying a common and equally altered expression in all samples (summarised in [table 2](#BMJOPEN2012002524TB2){ref-type="table"} and shown with full details in online [supplementary table S1](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). Other genes unselected by this analysis, but still abnormally expressed were also included in the study because of their role in specific processes and pathways, such as NADH mobilisation, cell cycle and immunity (see online [supplementary table S1](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)) and energetic metabolism (see online [supplementary table S2](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). GO classification of these genes showed similar profiles when comparing independently primary-deficient and secondary-deficient fibroblasts (see online [supplementary table S3](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). A lower stringency analysis showing the most altered biological processes and pathways selected 100 most altered GO in different functional categories (see online [supplementary table S4](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)) and 100 more distorted pathways (see online [supplementary table S5](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)) in CoQ~10~-deficient cells. See supplementary data for description of statistical analyses.

CoQ~10~ treatment modified the specific transcriptomic profile displayed by CoQ~10~-deficient fibroblasts (see online [supplementary tables S6 and S7](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). We classified genes into five groups according to the consequence of CoQ~10~ treatment on gene expression (see online [supplementary table S8](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1) for a graphical view). About 54% of probes with altered expression were unaffected by CoQ~10~ supplementation. Only 36% of probes showed partial or complete normalisation of expression and 2% showed inverse regulation ([figure 1](#BMJOPEN2012002524F1){ref-type="fig"}). Approximately 5% of probes were specifically altered after treatment in both deficient and non-deficient cells and 3% showed small or non-specific changes (these were not considered for further analysis). After statistical analysis, we obtained 70 altered GO with a significant p value (\<0.001) and an enrichment value that represents the most altered GO within each group (see online [supplementary table S9](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)).

![Cluster of genes differentially expressed in coenzyme Q~10~ (CoQ~10~)-deficiency and after CoQ~10~ supplementation. Four arrays of two representative fibroblasts from patients with Q deficiency were plotted with two arrays of control fibroblasts and nine arrays of five patient\'s fibroblasts with CoQ~10~ deficiency treated with 30 µM CoQ~10~. Activated genes were coloured in red and repressed ones in green. Between parentheses---group classification of genes after CoQ~10~ supplementation (see online supplementary Table S3).](bmjopen2012002524f01){#BMJOPEN2012002524F1}

Data have been deposited with the NCBI-GEO database, at <http://www.ncbi.nlm.nih.gov/geo/>, accession number GSE33941 (see online [supplementary table S10](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1) for an explanation). The functional description of each gene was updated from the GeneCard of The Human Gene Compendium (Weizmann Institute of Science), <http://www.genecards.org/>. See supplementary data for a full description of genes, biological process and pathways regulated in CoQ~10~ deficiency.

CoQ~10~-deficient fibroblasts readapt the energetic metabolism and CoQ~10~-treatment restores {#s3b}
---------------------------------------------------------------------------------------------

In CoQ~10~-deficient fibroblasts, mitochondrial functions, including respiratory chain and tricarboxylic acid (TCA) cycle, were repressed, whereas 9 of 10 steps in glycolysis and pyruvate metabolism were activated, including lactate and pyruvate dehydrogenases (see online [supplementary tables S2 and S4](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). Accordingly, genes involved in the negative regulation of glycolysis were downregulated, whereas those involved in its activation were upregulated (see online [supplementary table S2](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). Furthermore, genes involved in cytosolic NADH oxidation (cytochrome *b*~5~ and several oxidoreductases) were slightly repressed ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}). The expression of genes involved in cholesterol and fatty acid metabolism was downregulated ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}), as well all the GO related with lipid metabolism (see online [supplementary table S5](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)).

CoQ~10~ supplementation normalised the expression (either partially or completely) of genes involved in the glycolytic pathway and activated the expression of repressed respiratory chain genes, whereas the TCA cycle remained unaffected (see online [supplementary table S2](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). Most of the repressed enzymes of lipid metabolism and fatty acid β-oxidation remained downregulated ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}), whereas several other pathways, such as monocarboxylic acid transport and the insulin response, were normalised (see online [supplementary table S9](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). These results are in agreement with the recovery of aerobic metabolism observed in CoQ~10~-deficient fibroblasts after CoQ~10~ supplementation.[@R8] [@R16] [@R17]

CoQ~10~ deficiency induces specific adaptations of cells to promote survival {#s3c}
----------------------------------------------------------------------------

The major novel finding of transcriptome profiling in CoQ~10~-deficient fibroblasts was the altered expression of genes concerned with cell cycle and development and with resistance to stress and cell death ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}). This suggests both a remodelling of differentiation and growth maintenance and an increase of cell survival mechanisms. Specifically, genes involved in cell cycle activation and maintenance were upregulated, and genes involved in cell cycle regulation increased or decreased their expression depending of their activating or repressing roles. This proliferative response was also enhanced by the repression of cellular attachment factors and by the activation of extracellular matrix proteins that reduce cell attachment and favour cell division. In parallel, GO clusters favouring cell cycle and cell division were activated, and those inhibiting cell growth were repressed (see online [supplementary table S4](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). The differentiation of these cells was compromised because many required factors, transducers, antigens and structural proteins appeared downregulated, whereas repressors of differentiation during development were overexpressed ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}). See [supplementary material](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1) for a full description of genes, biological processes and related pathways.

Cell cycle activation was supported by the upregulation of CDK6 ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}), a cyclin-dependent kinase that induces entry into the S-phase, and by a robust repression (more than ninefold) of p21/CDKN1A, an inhibitor of cyclin-dependent kinase that blocks cell cycle at the G1/S check point to stimulate cell differentiation. Moreover, subsequent pathways inactivated by p21[@R23] were enhanced in CoQ~10~-deficient cells (see online [supplementary table S5](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)), as well as both transcription factors E2F7 and E2F8 ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}), which push the progression of the cell cycle, activate cell survival and inhibit apoptosis.[@R24]

Cell survival in CoQ~10~-deficient cells was improved by the induction of DNA-repairing mechanisms, and by the establishment of pathways that regulate Jun kinases and activate NAD(P)H-CoQ oxidoreductase, which are involved in stress responses ([table 2](#BMJOPEN2012002524TB2){ref-type="table"} and see online [supplementary table S4](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). Components of apoptosis and cell death pathways were systematically repressed ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}), including tumour suppressor genes, antigens, intracellular mediators and effectors of cell death. Also, cell surface receptors and modulators that inhibit apoptosis were greatly activated.

Interestingly, CoQ~10~ treatment did not alter the newly acquired resistance to cell death in CoQ~10~-deficient fibroblasts, kept cell growth activated, and allowed a higher degree of differentiation ([tables 2](#BMJOPEN2012002524TB2){ref-type="table"} and see online [supplementary table S8](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). However, genes controlling stress resistance pathways and cortical cytoskeleton were completely restored, as indicated by the shifts in gene expression listed in [table 2](#BMJOPEN2012002524TB2){ref-type="table"}. However, treated fibroblasts kept the DNA repair mechanism activated.

Signalling-related genes and pathways were differentially affected by CoQ~10~ deficiency, but most of immunity-related genes showed a general downregulation ([table 2](#BMJOPEN2012002524TB2){ref-type="table"}). Pathways and biological processes involved in immunity regulation were restored by CoQ~10~ supplementation ([table 2](#BMJOPEN2012002524TB2){ref-type="table"} and see online [supplementary table S5](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)).

Stable DNA methylation profile is responsible for the specific gene expression profile in CoQ~10~ deficiency {#s3d}
------------------------------------------------------------------------------------------------------------

CoQ~10~ supplementation modified the expression of 43% of genes that were abnormally expressed in CoQ~10~-deficient fibroblasts (see online [supplementary table S8](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). In the majority of these cases, expression levels were restored to those of control fibroblasts (20%), but few showed inverse regulation (2%) and others were specifically altered after CoQ~10~ treatment in both deficient and non-deficient cells (5%). The remaining 16% corresponded to partially restored genes, which slightly alter their expression level without changing the CoQ~10~-deficient pattern. These genes along with the unaffected (54%) constitute 72% of regulated genes in CoQ~10~ deficiency, which were not significantly altered after CoQ~10~ supplementation.

To explain this differential response to respiratory dysfunction, we analysed the DNA-methylation profile of 20 among the most altered genes listed in [table 2](#BMJOPEN2012002524TB2){ref-type="table"}. These genes encompass the main biological processes and pathways affected by CoQ~10~ deficiency ([table 3](#BMJOPEN2012002524TB3){ref-type="table"}). Upregulated genes, which were unaffected by CoQ~10~ supplementation, had less-defined DNA methylation sites in their promoter regions.

###### 

Epigenetic modifications in CoQ10 deficiency owing to DNA (CpG) methylation/demethylation

                                         Demethylations in CoQ~10~ deficiency   Methylations in CoQ~10~ deficiency                                                                       
  ----------- -------- ---- ------------ -------------------------------------- ------------------------------------ ---------------------- ------------- --------- -------------------- ----------
  POSTN       73.8     U    5 (P)        2 (16 fold)                            50%/3%                               Close together (P)     0             --        --                   --
  GABBR2      13.8     U    101 (P,I)    5 (40%)                                47%/37%                              Close together (P)     14 (6-fold)   10%/22%   Close together (P)   --15%
  VCAN        2.8      U    58 (P,E,I)   5 (2-fold)                             12%/7%                               Scattered groups       3 (90%)       9%/17%    Dispersed (I)        --
  TNFRSF10D   2.4      U    59 (P,E,I)   27 (2-fold)                            60%/25%                              Scattered groups (P)   0             --        --                   --
  FOXP1       2.3      U    85 (I)       11 (2-fold)                            57%/32%                              Scattered groups       2 (3-fold)    7%/19%    Close together       --
  END1        −3.0     U    25 (P)       0                                      --                                   --                     0             --        --                   --
  PARP14      −3.1     U    29 (P)       0                                      --                                   --                     3 (3-fold)    5%/19%    Dispersed            --
  CPE         11.6     pR   26 (P,I)     3 (4-fold)                             20%/6%                               Dispersed              0             --        --                   +2-fold
  ARL4C       4.2      pR   63 (P,E,I)   5 (90%)                                52%/28%                              Scattered groups       9 (60%)       16%/28%   Scattered groups     +7%
  HOXA11      −4.3     pR   17 (P)       0                                      --                                   --                     8 (4-fold)    5%/20%    Close together (P)   --3-fold
  AEBP1       66.1     R    80 (P,E,I)   8 (25%)                                76%/61%                              Scattered groups       8 (3-fold)    10%/27%   Widely dispersed     --
  CYP1B1      4.7      R    24 (P)       0                                      --                                   --                     0             --        --                   --
  CHURC1      3.5      R    20 (P,E,I)   1 (50%)                                11%/7%                               \(I\)                  0             --        --                   --
  PYGL        −2.5     R    84 (P,E,I)   8 (2-fold)                             12%/6%                               Close together (E)     1 (3-fold)    4%/13%    \(P\)                --
  XAF1        −3.0     R    25 (P,E,I)   0                                      --                                   --                     0             --        --                   --
  EPSTI1      −5.9     R    34 (P,E)     0                                      --                                   --                     7 (2-fold)    27%/37%   Scattered groups     --
  MCAM        −7.7     R    74 (P,E,I)   0                                      --                                   --                     0             --        --                   --
  MLPH        −8.5     R    8 (P)        0                                      --                                   --                     0             --        --                   --
  PCSK2       −94.3    O    32 (P)       0                                      --                                   --                     0             --        --                   --
  GRP         −263.6   O    73 (P,E,I)   20 (two fold)                          53%/35%                              Scattered groups       6 (50%)       28%/35%   Close together (P)   --

\*Full change (FC) in coenzyme Q~10~ (CoQ~10~) deficiency (patient samples (SAM) analysis; R=1.5; false discovery rate (FDR)=0%) ran with Affymetrix GeneChip Human Genome U133 Plus 2.0 Array. Full details are shown in [table 2](#BMJOPEN2012002524TB2){ref-type="table"}.

†Effect of CoQ~10~ supplementation on gene expression in CoQ~10~ deficiency ( for more information see online [supplementary table S8](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)): unaffected genes by CoQ~10~ treatment (U), genes that restored the expression either partial (pR) or completely (R) and genes with opposite regulation after CoQ~10~ supplementation than in CoQ~10~ deficiency (O).

‡Number of CpG islands analysed. In parenthesis, gene location of CpG islands: promoter (P), first exon (E) and first intron (I).

§Significant methylated CpGs for each gene in control and CoQ~10~-deficient fibroblast. Significance determined by t test (p\<0.01). In parenthesis, fold change in methylation degree (small changes, in %). Non-significant changes in methylation (−).

¶Methylation degree (mean of significant CpG). Values represent the % of CpG\'s methylation of both control (C) and patient deficient in CoQ~10~ (P).

\*\*Location of significant CpGs. In parenthesis, gene location: promoter (P), first exon (E) and first intron (I).

††Significant changes in CpG methylation owing to CoQ~10~ supplementation in CoQ~10~ deficiency. Positive values, an increase in the methylation degree and negative values, demethylations. Significance determined by t test (p\<0.01) between CoQ~10~-supplemented fibroblasts and untreated CoQ~10~-deficient fibroblasts. Non-significant changes in methylation (−).

Genes with partial restoration of their expression after CoQ~10~ supplementation showed precise methylation and demethylation profiles that may explain their altered expression during CoQ~10~ deficiency. The methylation degree of these genes changed after treatment, and may be responsible for the modulation of expression ([table 3](#BMJOPEN2012002524TB3){ref-type="table"}). The patterns of methylation of activated and repressed genes in CoQ~10~ deficiency that could be normalised by CoQ~10~ supplementation, were either unaffected or only slightly affected by the treatment, and we did not detect new methylation sites after CoQ~10~ supplementation.

However, a few genes showed significant differences in the methylation degree after the treatment, which correspond to the partially restored genes that maintain the specific expression pattern of untreated CoQ~10~ deficient cells at a lower level.

Finally, reviewing the biological processes and molecular functions of regulated genes in CoQ~10~ deficiency, the main adaptation for cell survival activated genes by DNA demethylation, which increased the expression of genes involved in cell cycle activation, apoptosis inhibition, and cell stress resistance, meanwhile the undifferentiated state could be owing to gene repression by DNA methylation, which decreased the expression of genes involved in cell differentiation. CoQ~10~ treatment did not alter the methylation degree of these genes and subsequently the expression level was maintained.

Discussion {#s4}
==========

CoQ~10~-deficient fibroblasts readapt the energetic metabolism and CoQ~10~-treatment restores {#s4a}
---------------------------------------------------------------------------------------------

CoQ~10~ is an essential component of the mitochondrial respiratory chain,[@R1] therefore dysfunctional mitochondria are a common finding in both primary CoQ~10~ deficiencies[@R3; @R4; @R5; @R6; @R7] and secondary forms.[@R8; @R9; @R10; @R11; @R12; @R13] Although each form presents a specific clinical phenotype, all these conditions display a substantial reduction of cellular CoQ~10~ content and deficit in the mitochondrial enzymatic activities of respiratory chain ([table 1](#BMJOPEN2012002524TB1){ref-type="table"}). Accordingly to these results, we have shown here that fibroblasts from patients with CoQ~10~ deficiency have reorganised their genetic resources to cope with this mitochondrial dysfunction. Consistent with the role of CoQ~10~ in bioenergetics, the lack of CoQ~10~ would force the cell to support it mainly by glycolysis, whereas both mitochondrial lipid metabolism and respiratory chain were repressed (see online [supplementary tables S2 and S4](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). These findings, together with the mild repression of cytosolic enzymes that oxidise NADH (cytochrome *b*~5~ and its oxidoreductases listed in [table 2](#BMJOPEN2012002524TB2){ref-type="table"}) could indicate that NADH is mainly used for biosynthetic purposes rather than for energy production.

Supplementation with CoQ~10~, the current therapy for all forms of CoQ~10~ deficiency, restored respiration through enhanced sugar utilisation, but did not stimulate lipid metabolism. The expression of genes involved in the glycolytic pathway was partially or completely normalised after CoQ~10~ treatment, whereas the repressed genes involved in the respiratory chain were activated. The TCA cycle remained unaffected (see online [supplementary table S2](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)). These results are in agreement with the recovery of aerobic metabolism observed in CoQ~10~-deficient fibroblasts after CoQ~10~ supplementation.[@R8] [@R16] [@R17]

CoQ~10~ deficiency induces a stable survival adaptation of cells {#s4b}
----------------------------------------------------------------

CoQ~10~-deficient fibroblasts adapted several physiological processes to acquire a cellular-resistance state for survival under the conditions of mitochondrial dysfunction induced by CoQ~10~ deficiency. The new genetic pattern increases cell survival by activating cell cycle and growth, maintaining an undifferentiated phenotype, upregulating stress-induced proteins and inhibiting apoptosis and cell death pathways. These results recapitulate a survival network that can be observed in nutritional stress such as when cells are grown in galactose-enriched media.[@R25]

The survival adaptation shown by CoQ~10~-deficient cells included a global resistance mechanism that is observed also during the initial phase of tumorigenesis. In fact, the CoQ~10~-deficient expression profile was very similar to that described during myeloid cell transformation[@R26] and breast tumours.[@R27] Moreover, some of the regulated genes in CoQ~10~ deficiency (listed in [table 2](#BMJOPEN2012002524TB2){ref-type="table"} as italicised letter) are used as biomarkers in several types of cancer,[@R28] like KRT34, the cell cycle-related POSTN, MCAM, EFEMP1 and VCAN, and the apoptotic and cell resistance-related CYP1B1, XAF1 and TNFRSF10D. Although these biomarkers behaved in CoQ~10~ deficiency (increased or decreased) as described by Yoo *et al*,[@R28] there is no sign of tumour formation reported in the patients so far. In addition, cellular senescence, a defining feature of premalignant tumours,[@R29] is characterised by a gene expression pattern similar to that of CoQ~10~-deficient fibroblasts (see online [supplementary table S5](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2012-002524/-/DC1)).

Supplementation with CoQ~10~ enhanced both stress response and immunity pathways. Although the pathway of cell death was partially restored, cell cycle and growth, and the mechanisms to prevent differentiation and development were not. These results indicate that the mitochondrial dysfunction owing to CoQ~10~ deficiency induces a stable survival adaptation of somatic cells in patients at early or postnatal development, and we speculate that cells unable to institute, or to maintain, this survival mechanism during differentiation will die, contributing to the pathological phenotype.

A stable DNA methylation profile is responsible of specific gene expression in CoQ~10~ deficiency {#s4c}
-------------------------------------------------------------------------------------------------

The cellular adaptation to CoQ~10~ deficiency-enhanced DNA demethylation of genes that regulate cell cycle activation, apoptosis inhibition and cell stress resistance as part of an adaptation survival mechanism. Comparable results were observed in several models of epigenetic regulation by demethylation (see online supplementary table S5), whereas DNA methylation inhibits activation of genes related to tumorogenesis and apoptosis.[@R30]

Pathways unaffected by CoQ~10~ treatment corresponded to stably demethylated genes, whereas those that responded to CoQ~10~ supplementation were controlled by genes with unchanged methylation patterns.

We did not find changes in the methylation degree of all genes affected by CoQ~10~ deficiency, suggesting that other modalities of gene regulation are responsible, including epigenetic mechanisms such as histone modifications by methylation and acetylation, or even DNA methylation in CpG islands other than those studied here. Interestingly, it has been reported that CoQ~10~ regulates lipid metabolism in mice liver without any effect on the DNA methylation profile,[@R31] indicating that supplemented CoQ~10~ by itself may not alter the DNA methylation pattern that cells acquired during the survival adaptation to CoQ~10~ deficiency.

Mechanisms unaffected by therapy corresponded to stably DNA demethylated genes, which were responsible for the acquisition of the undifferentiated state for survival and resistance that cells obtain during the adaptation to CoQ~10~ deficiency, whereas the responsive to CoQ~10~ supplementation were controlled by genes with unchanged methylation patterns and correspond mainly to metabolic genes and those related with the restoration of mitochondrial function.

We propose that these epigenetic changes may be established as early as during the fetal life[@R32] in order to cope with CoQ~10~ deficiency; these cells then maintain this adaptive response throughout their life. We speculate that cells unable to maintain this survival mechanism during differentiation would die contributing to the pathological phenotype.

Our model has some limits: we treated cells only for 1 week and in principle we cannot rule out that prolonged exposure to CoQ~10~ could restore also some of the other unaffected pathways. Alternatively, incomplete recovery of the gene expression profiles could be explained by the fact that exogenous CoQ~10~ can rescue the bioenergetic defect, but not all other functions of CoQ~10~ in these cells, as it has been observed in other organisms.[@R33]
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